Regeneron Pharmaceuticals Inc logo

Regeneron Pharmaceuticals Inc

REGN
Healthcare|Biotechnology|USA
$763.04
+1.19 (+0.16%)
DCF (FCF)
$641.30
Tangible Book
$283.77
Graham Number
$532.32
Earnings Power
$496.16

Upcoming Data Readouts (103)

May 2026
Est. completion
P1Relapsed/Refractory Aggressive B-Cell Lymphoma
A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies
NCT02651662n=105
Jun 2026
Est. completion
P2Venous Thromboembolism
A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)
NCT06299111n=195
Jun 2026
Est. completion
Chronic Rhinosinusitis With Nasal Polyps
Dupilumab Treatment Effects in an Ethnically Diverse Population With Chronic Rhinosinusitis With Nasal Polyposis
NCT05246267n=60
Jun 2026
Est. completion
Chronic Kidney Disease (CKD)
An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant
NCT05106387n=20
Jun 2026
Est. completion
P1Head and Neck Cancer
A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer
NCT04722523n=40
Jun 2026
Est. completion
P4Asthma
Viral Infection in Asthma (VIA) Study
NCT04380038n=60
Jul 2026
Est. completion
Asthma
Description of Characteristics, Such as Age, Previous and Concurrent Treatments, Associated Diseases, of Patients With Asthma Treated With Dupilumab (DUPIXENT)
NCT04550962n=376
Jul 2026
Est. completion
P2B-cell Non-Hodgkin Lymphoma (B-NHL)
A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies
NCT03888105n=515
Jul 2026
Est. completion
P1Healthy Volunteer
Phase 1 Safety and Tolerability Study of ALN-F1202 in Healthy Adults
NCT06669234n=56
Aug 2026
Est. completion
P2Chronic Rhinosinusitis Without Nasal Polyps
A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps
NCT06691113n=60
Aug 2026
Est. completion
P4Diabetic Macular Edema (DME)
High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy
NCT06662994n=15
Aug 2026
Est. completion
P1P2Advanced Solid Tumors
A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
NCT04626635n=933
Sep 2026
Est. completion
P4Eosinophilic Esophagitis (EoE)
Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE)
NCT06665971n=30
Sep 2026
Est. completion
Prurigo Nodularis
Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study
NCT05991323n=100
Oct 2026
Est. completion
P3Atopic Dermatitis
Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)
NCT02612454n=880
Nov 2026
Est. completion
P2Asthma, Allergic
Dupilumab Effects Against Aeroallergen Challenge
NCT05720325n=88
Nov 2026
Est. completion
P2Overweight or Obesity
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US
NCT07431086n=120
Dec 2026
Est. completion
P3Chronic Obstructive Pulmonary Disease
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
NCT06208306n=700
Dec 2026
Est. completion
P2Carcinoma, Non-Small-Cell Lung
Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC
NCT06623656n=112
Dec 2026
Est. completion
P4Atopic Dermatitis
Ethnic Differences in Mechanisms of Action of Dupilumab
NCT05268107n=30

Awaiting Results (14)

Trials past primary completion date but still active — data readout may be imminent.

May 2026
A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy
NCT05568459
Apr 2026
Registry of Asthma Patients Initiating DUPIXENT®
NCT04287621
Apr 2026
P2
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery
NCT06161441
Apr 2026
Observational Study of Canadian Patients (6 Years or Older) Receiving Dupixent® for Moderate to Severe Atopic Dermatitis
NCT06099704
Feb 2026
P2
A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have
NCT05831176
Feb 2026
Parkinson's Disease Progression Study
NCT06219629
Jan 2026
P1
A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.
NCT05704634
Dec 2025
P2
A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity
NCT06373146
Sep 2025
P2
PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung
NCT05553834
Sep 2025
P2
Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer
NCT04050436

Recent Press Releases